Science
Next-generation Anti-CD47 Antibody Therapeutics
CD47 is a protein expressed on most cells, including tumor cells. When overexpressed on tumor cells, CD47 communicates a “don’t eat me” signal to cells of the immune system so that tumor cells can evade detection. CD47 is a validated clinical target for a new class of checkpoint inhibitors that work by directing both innate and adaptive immune responses.
Blocking + Killing Activity = Potential for an Improved Efficacy Profile
As expected from anti-CD47 antibodies, our antibodies work by blocking the “don’t eat me” signal, activating an innate immune response. In addition to this signal blocking, our antibodies also directly kill tumor cells and further activate the adaptive immune response. Our antibodies are the only anti-CD47 antibodies with both of these anti-tumor activities.
Preferential + Selective Binding = Potential for an Improved Safety Profile
Our antibodies bind preferentially to tumor cells, instead of to normal cells (such as red blood cells). In addition, they bind even more potently to tumors in their acidic microenvironment (low pH). Only our antibodies offer these important preferential and selective tumor binding advantages.
Click / tap on the figures below for larger views.
Arch’s antibodies are the only anti-CD47 antibodies that both block the “don’t eat me” signal and directly kill tumor cells
Arch’s anti-CD47 antibodies disrupt the CD47/SIRPα “don’t eat me signal” to activate phagocytosis of tumor cell by macrophages
Figure-1
CD47 prevents tumor cell phagocytosis by macrophage
Figure-2
Anti-CD47 antibodies disrupt checkpoint inhibition
Figure-3
Macrophage engulfs tumor cell to initiate an immune response
Arch’s anti-CD47 antibodies also directly kill tumor cells (non ADCC)
Figure-4
Tumor cell expressing CD47
Figure-5
Arch’s next-generation anti-CD47 antibodies bind to tumor cell
Figure-6
Arch’s next-generation anti-CD47 antibodies directly kill tumor cells
Arch’s anti-CD47 antibodies have preferential and selective binding
Figure-7
Arch’s next-generation anti-CD47 antibodies bind preferentially to tumor cells, instead of to normal cells